Review evaluates PROX1's dual role in cancer as an oncogenic driver and tumor suppressor, highlighting its therapeutic implications.
Introduction: PROX1 is a conserved transcription factor with context-dependent roles in cancer. This review evaluates its dual nature as both an oncogenic driver and a tumor suppressor. Methods: This review, which involved scanning of pertinent literature, describes and evaluates recent research on the biological functions and mechanisms of PROX1 in malignancies Results: The functions of PROX1 in cancer are highly context-dependent. In gastric cancer, colorectal cancer, and glioma, PROX1 acts as an oncogenic driver. Conversely, in pancreatic ductal adenocarcinoma, it serves as a tumor suppressor. In hepatocellular carcinoma, breast cancer, thyroid carcinoma, and vascular tumors, PROX1 exhibits a dual role. Specifically, in different types of vascular tumors, the expression of PROX1 is more closely associated with the lymphatic endothelial phenotype. Although it also partially indicates a malignant phenotype, this association is not entirely consistent. Discussion: The functional switch of PROX1 is primarily governed by its subcellular localization and interaction with specific targets. Its significant heterogeneity across cancer stages necessitates the development of more precise, context-aware diagnostic and treatment protocols Conclusion: PROX1 is a multifaceted transcription factor, with both tumor-suppressive and oncogenic roles in diverse cancers. Its diverse functions underscore the necessity for a nuanced understanding of its mechanisms in different cancer types and suggest that PROX1 holds significant potential as a therapeutic target and prognostic biomarker. This provides new avenues for the prevention and treatment of tumor diseases in the future.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: